title: The inhibitory effect of rosmarinic acid on complement involves the C5 convertase.
abstract: Rosmarinic acid (RA), a naturally occurring extract from Melissa officinalis, inhibits several complement-dependent inflammatory processes and may have potential as a therapeutic agent for the control of complement activation in disease. Rosmarinic acid has been reported to have effects on both the classical pathway C3-convertase and on the cobra venom factor-induced, alternative pathway convertase. In order to define the mechanism of inhibition, the effect of RA on classical and alternative pathway lysis, C1q binding, the classical pathway convertase, the alternative pathway convertase, membrane attack pathway lysis and the generation of fragments of C3 and C5 during activation, was tested in vitro. The results showed that RA inhibited lysis by the classical pathway more than by the alternative pathway. This effect was dose-dependent with maximum inhibition of classical pathway lysis observed at 2.6 mmoles of RA. There was little effect on C1q binding or on the classical and alternative pathway convertases. However, there was highly significant inhibition of lysis of pre-formed EA43b cells by dilutions of human or rabbit serum in the presence of RA (1 mM); this was accompanied by inhibition of C5a generation. We conclude that the inhibitory effect of RA involves the C5 convertase. Such inhibition could be advantageous to the host in disorders where the terminal attack sequence plays a role in pathogenesis.
authors.affiliation: Department of Nephrology, Prince Henry Hospital, Sydney, NSW, Australia.
authors.forename: P W
authors.initials: PW
authors.lastname: Peake
authors.forename: B A
authors.initials: BA
authors.lastname: Pussell
authors.forename: P
authors.initials: P
authors.lastname: Martyn
authors.forename: V
authors.initials: V
authors.lastname: Timmermans
authors.forename: J A
authors.initials: JA
authors.lastname: Charlesworth
mesh_terms: D000818:Animals; D002934:Cinnamates / Q000494:pharmacology*; D050577:Complement C3-C5 Convertases / Q000037:antagonists & inhibitors*; D003169:Complement Inactivator Proteins / Q000494:pharmacology*; D003170:Complement Pathway, Alternative / Q000187:drug effects; D003171:Complement Pathway, Classical / Q000187:drug effects; D053630:Depsides; D006801:Humans; D066298:In Vitro Techniques; D000097123:Rosmarinic Acid
chemical_list: D002934:Cinnamates; D050577:Complement C3-C5 Convertases; D003169:Complement Inactivator Proteins; D053630:Depsides; D000097123:Rosmarinic Acid